AIOG, on behalf of EBCTCG's

Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 529-529

10.1200/jco.2014.32.15_suppl.529